Prof. Luigi Naldini will present updates on the efficacy of Temferon in pre-clinical solid tumor models and preliminary clinical biological data confirming in patients MILAN, Italy and NEW YORK , May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini , Ph.D., M.D., co-founder and Executive Scientific Board
Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025 Net exchange rate gain of €2.3 million Tax credit of €6.4 million MILAN , Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A .
MILAN, Italy and NEW YORK , April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the
MILAN and NEW YORK , March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the U.S.
MILAN, N.Y. , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC
• Signs of intra-tumor pro-inflammatory state in patients • Temferon™ induced immune system reset in preclinical studies • Macrophage and T cell profiles in patients’ tumor microenvironment echo preclinical findings MILAN, Italy and NEW YORK , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science
Current dose escalation study data shows a median overall survival of 17 months Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimen Cash and cash equivalents of €34.7 million as of June 30, 2022 , providing a cash runway until the end of 2024 €1.8 million unrealized
MILAN, Italy and NEW YORK , Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several
MILAN, Italy and NEW YORK , Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several
Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets MILAN, Italy , July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion in
